Antibodies and vaccines for use in therapeutic and diagnostic methods for α-synuclein-related disorders
US9315569B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 21, 2014 |
| Grant date | Apr 19, 2016 |
| Priority date | — |
| Expiry date | Jul 21, 2034 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/839
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of treating or delaying onset of a neurodegenerative disorder with α-synuclein pathology in an individual comprise administering an antibody which is produced from a stabilized soluble α-synuclein oligomer and capable of binding a stabilized soluble α-synuclein oligomer, the stabilized soluble α-synuclein oligomer having a lower formation rate to a non-soluble aggregated form than a non-stabilized soluble oligomer of the α-synuclein. The antibody has been collected from a non-human animal to which stabilized soluble α-synuclein oligomer had been administered or has been produced by hybridoma technology, phage display, ribosome display, mammalian cell display or bacterial display, and the disorder with α-synuclein pathology is characterized by deposition of Lewy bodies and Lewy neurites or is selected from the group consisting of Parkinson's disease (PD), dementia with Lewy bodies (DLB), the Lewy body variant of Alzheimer's disease, and multiple system atrophy (MSA).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.